（优质医学）MSI微卫星不稳定性.pptVIP

DFS in dMMR patients HR: 2.80 (0.98-8.97) p=0.05 Stage II (N=102) Stage III (N=63) Untreated 55 87% Treated 47 72% Untreated 24 62% Treated 39 67% N 5 yr DFS N 5 yr DFS 0 10 20 30 40 50 60 70 80 90 100 0 1 2 3 4 5 Years % Disease Free 0 10 20 30 40 50 60 70 80 90 100 0 1 2 3 4 5 Years % Disease Free II期结肠癌，dMMR患者5-FU辅助化疗带来不利影响 III期结肠癌，dMMR患者5-FU辅助化疗不获益 * DFS in pMMR patients HR: 0.84 (0.57-1.24) p=0.38 Stage II (N=428) Stage III (N=434) Untreated 72% Treated 77% Untreated 41% Treated 58% 5 yr DFS 5 yr DFS 0 10 20 30 40 50 60 70 80 90 100 0